食品药品监督管理局
中国
医学
业务
环境卫生
政治学
法学
作者
Yan‐Ming Xie,Xing Liao,Yu-Bin Zhao,Mingquan Li,Yunling Zhang,Rong Ma,Shao-xiang Xian,Jian Liu,Suyun Li,Zehuai Wen,Zhong-Qi Yang,Jiandong Zou,Hongsheng Sun,Yan He,Xuelin Li,Junjie Jiang,Zhifei Wang,Yuanyuan Li,Lian-Xin Wang,Yan-Peng Chang
标识
DOI:10.4268/cjcmm20131801
摘要
It is of vital significance to conduct active post-marketing surveillance of Chinese medicine, as an active response to laws, rules and guidelines issued by the China food and drug administration. The standards for technological specifications based on expert consensus have been drafted. These will provide technological support in evaluating adverse drug reactions (ADRs) or adverse drug events (ADEs). The technological specifications for post-marketing surveillance focus on two surveillance designs; one is a large sample registry study to explore general population ADR/ADE characteristics, the other is a nested case-control study to explore the characteristic and mechanisms of ADRs.
科研通智能强力驱动
Strongly Powered by AbleSci AI